PCa Recurrence Predictors in Whole Gland Cryotherapy Identified
Older age and high-risk disease are among the factors independently associated with biochemical recurrence of prostate cancer following whole gland cryotherapy.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
Non-Standard Therapies Used in 20% of Localized High-Risk PCa Cases
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes. -
Prostate Cancer ADT Found to Increase Depression Risk
Men who receive androgen deprivation therapy after radical prostatectomy have a nearly 2-fold increased risk of depression compared with those who receive no post-surgical treatment. -
Adjuvant Docetaxel Possibly Beneficial in High-Risk Prostate Cancer
In a study, adding docetaxel to androgen deprivation and radiation therapy for selected men with high-risk localized prostate cancer improved overall and metastasis-free survival.
Latest Prostate Cancer News
Darolutamide Delays Pain Progression, Deterioration in Urinary Symptoms in High-Risk Nonmetastatic CRPC
Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
Prostate Cancer Detection Greater With Targeted Plus Systematic Biopsy
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
Advanced, Fatal Prostate Cancer Linked to High Visceral Fat
Greater visceral and thigh subcutaneous fat are associated with higher risks of advanced and fatal prostate cancer (PCa), according to a new prospective study. In addition, visceral fat is associated with a higher risk of these outcomes among men with a lower body mass index (BMI). Investigators found no association between any adiposity measure and…
Real-World Prostate Cancer Active Surveillance Less Than Ideal
In a study of prostate cancer patients from North Carolina, only 15% received monitoring as recommended by the NCCN.
Enzalutamide Ups Survival in Metastatic Hormone-Sensitive PCa
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.
PET/CT Imaging for Recurrent PCa Detection More Accurate With PSMA
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
More Advanced PCa Diagnoses Followed USPSTF Screening Recommendations
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
Visceral Metastases on the Rise in Metastatic Prostate Cancer
The proportion of men with metastatic prostate cancer who develop visceral metastases rose from 26% in 2009 to 40% in 2016, a study found.
Adding Apalutamide to ADT Prolongs Survival in mCSPC
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
Radiation + ADT Superior for Prostate Cancer Salvage Therapy
Men with recurrent prostate cancer after radical prostatectomy had better 10-year metastasis-free survival when they received radiation therapy (RT) plus short-term hormone therapy rather than RT alone.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
